1,101 results match your criteria Journal of cardiovascular pharmacology and therapeutics[Journal]


Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure.

J Cardiovasc Pharmacol Ther 2019 Feb 20:1074248419829168. Epub 2019 Feb 20.

1 Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, Osakasayama, Japan.

Background:: Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown.

Purpose:: The present study assessed the chronic effects of IVA and β-blocker on the systemic and local sympathetic nervous systems of hypertensive animals with HF.

Methods And Results:: The Dahl salt-sensitive rats received chronic IVA, bisoprolol (BIS), or placebo (CTL) therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248419829168DOI Listing
February 2019

The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

J Cardiovasc Pharmacol Ther 2019 Feb 17:1074248419829172. Epub 2019 Feb 17.

1 Division of Cardiology, Department of Medicine, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Pulmonary hypertension (PH) and its severe subtype pulmonary arterial hypertension (PAH) encompass a set of multifactorial diseases defined by sustained elevation of pulmonary arterial pressure and pulmonary vascular resistance leading to right ventricular failure and subsequent death. Pulmonary hypertension is characterized by vascular remodeling in association with smooth muscle cell proliferation of the arterioles, medial thickening, and plexiform lesion formation. Despite our recent advances in understanding its pathogenesis and related therapeutic discoveries, PH still remains a progressive disease without a cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248419829172DOI Listing
February 2019

Ticagrelor Does Not Protect Isolated Rat Hearts, Thus Clouding Its Proposed Cardioprotective Role Through ENT 1 in Heart Tissue.

J Cardiovasc Pharmacol Ther 2019 Feb 11:1074248419829169. Epub 2019 Feb 11.

1 Departments of Physiology and Cell Biology, University of South Alabama College of Medicine, Mobile, AL, USA.

P2Y receptor-blocking drugs given at reperfusion offer protection against myocardial infarction in animal models of transient coronary occlusion. Two recent reports concluded that ticagrelor was more cardioprotective than clopidogrel and attributed this to ticagrelor's unique ability to raise tissue adenosine by blocking the equilibrative nucleoside transporter 1. Indeed, an adenosine receptor blocker attenuated ticagrelor's protection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248419829169DOI Listing
February 2019
2 Reads

De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives.

J Cardiovasc Pharmacol Ther 2019 Feb 5:1074248418823724. Epub 2019 Feb 5.

1 2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y receptor inhibitors, prasugrel and ticagrelor, are proposed as "first-line" antiplatelet agents in the absence of contraindications and up to a year from the index event. However, de-escalation of treatment to clopidogrel occurs with a variable frequency in real-life practice, most commonly due to an increased bleeding potential, more frequent side effects, and a higher cost for the novel agents. Pharmacodynamic studies provide most of the data on guidance for de-escalation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418823724DOI Listing
February 2019
2 Reads

The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.

J Cardiovasc Pharmacol Ther 2019 Jan 10:1074248418817345. Epub 2019 Jan 10.

6 Faculty of pharmacy, Cairo University, Giza, Egypt.

Background:: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors are used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The current study investigated the effects of vildagliptin, DPP-4 inhibitor, compared to metformin on endothelial function and blood pressure through vascular endothelial growth factor (VEGF) modulation in patients with T2DM and hypertension.

Methods:: This study was designed as a randomized controlled parallel study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418817345DOI Listing
January 2019
4 Reads

Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience.

J Cardiovasc Pharmacol Ther 2019 Jan 6:1074248418823016. Epub 2019 Jan 6.

1 Cardiology Department, The James Cook University Hospital, Middlesbrough, United Kingdom.

Aims:: There are limited data on aspirin (ASA) desensitization for patients with coronary disease. We present our experience with a rapid nurse-led oral desensitization regimen in patients with aspirin sensitivity undergoing coronary angiography.

Methods:: This single-center retrospective observational study includes patients with a history of ASA sensitivity undergoing coronary angiography with intent to perform percutaneous coronary intervention (PCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418823016DOI Listing
January 2019
3 Reads

Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.

J Cardiovasc Pharmacol Ther 2019 Jan 1:1074248418821712. Epub 2019 Jan 1.

1 First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Background:: Proper anticoagulation is a crucial therapeutic regimen in atrial fibrillation (AF).

Objectives:: To evaluate the real-life anticoagulation prescriptions of AF patients upon hospital discharge.

Methods:: We studied 768 patients with comorbid AF who were discharged from the cardiology ward of a tertiary hospital. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418821712
Publisher Site
http://dx.doi.org/10.1177/1074248418821712DOI Listing
January 2019
3 Reads

Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.

J Cardiovasc Pharmacol Ther 2019 Jan 2:1074248418821721. Epub 2019 Jan 2.

4 Department of Biostatistics, Cardiovascular Research center, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.

Objective:: Chemotherapy-induced cardiotoxicity is a major and leading cause of death in breast cancer survivors. It can present decades after chemotherapy and can manifest in different ways; some chemotherapeutic agents have a powerful dose-dependent relationship with cardiotoxicity. The aim of this study was to investigate the effect of rosuvastatin on preventing chemotherapy-induced cardiotoxicity in patients with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418821721DOI Listing
January 2019
1 Read

Unfractionated Heparin Protocol During Percutaneous Left Ventricular Mechanical Circulatory (Impella) Support.

J Cardiovasc Pharmacol Ther 2018 Dec 20:1074248418816322. Epub 2018 Dec 20.

5 University of California, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418816322DOI Listing
December 2018
2 Reads

Prospects for the Primary Prevention of Myocardial Infarction and Stroke.

J Cardiovasc Pharmacol Ther 2018 Dec 18:1074248418817344. Epub 2018 Dec 18.

1 Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA.

Cardiovascular disease (CVD), principally myocardial infarction (MI) and stroke, is the leading clinical and public health problem in the United States and is rapidly becoming so worldwide. Their primary prevention is promising, in theory, but difficult to achieve in practice. The principal modalities that have demonstrated efficacy include therapeutic lifestyle changes (TLCs) and adjunctive drug therapies under the guidance of the health-care provider and tailored to the individual patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418817344DOI Listing
December 2018
1 Read

Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction.

J Cardiovasc Pharmacol Ther 2018 Dec 18:1074248418812167. Epub 2018 Dec 18.

1 Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.

Acute myocardial infarction (MI) is still a large source of morbidity and mortality worldwide. Although early reperfusion therapy has been prioritized in the modern era of percutaneous coronary intervention and thrombolysis, attempts at incremental improvements in clinical outcomes by reducing MI size have not been successful so far. Herein, we review the studies that have evaluated immediate-onset antiplatelet therapy as attempts to improve meaningful clinical outcomes in ST-segment elevation MI (STEMI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418812167DOI Listing
December 2018
12 Reads

Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not: A Langendorff Study.

J Cardiovasc Pharmacol Ther 2018 Nov 29:1074248418810811. Epub 2018 Nov 29.

1 Department of Cardiology at Boston Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

Introduction:: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418810811DOI Listing
November 2018
1 Read

Chrysin Suppresses Vascular Endothelial Inflammation via Inhibiting the NF-κB Signaling Pathway.

J Cardiovasc Pharmacol Ther 2018 Nov 29:1074248418810809. Epub 2018 Nov 29.

1 Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

The vascular endothelium is a continuous layer of flat polygonal cells that are in direct contact with the blood and participate in responses to inflammation. Chrysin is a flavonoid compound extracted from plants of the genus Asteraceae with a wide range of pharmacological activities and physiological activities. Here, we studied the effects of chrysin on the regulation of the proadhesion and pro-inflammatory phenotypes of the endothelium both in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418810809DOI Listing
November 2018
1 Read

The Protective Effects of Preconditioning With Dioscin on Myocardial Ischemia/Reperfusion-Induced Ventricular Arrhythmias by Increasing Connexin 43 Expression in Rats.

J Cardiovasc Pharmacol Ther 2018 Nov 26:1074248418801567. Epub 2018 Nov 26.

1 Department of Cardiology, Tangdu Hospital, Air Force Military Medical University, Xi'an, China.

Myocardial ischemia-reperfusion (IR) injury is associated with high disability and mortality worldwide. This study was to explore the roles of dioscin in the myocardial IR rats and discover the related molecular mechanisms. Rats were divided into 5 groups: sham, IR, IR + 15 mg/kg dioscin, IR + 30 mg/kg dioscin, and IR + 60 mg/kg dioscin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418801567DOI Listing
November 2018
1 Read

Employing the Sirolimus-Eluting Poly (Propylene Carbonate) Mesh for the Prevention of Arteriovenous Graft Stenosis in Rats.

J Cardiovasc Pharmacol Ther 2018 Nov 26:1074248418806060. Epub 2018 Nov 26.

1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Poly (propylene carbonate, PPC) is a new member of the aliphatic polyester family. An outstanding feature of PPC is that it produces mainly water and carbon dioxide when degraded in vivo, causing minimal side effects. This unique property together with excellent biocompatibility and biodegradability makes PPC a promising material for drug delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418806060DOI Listing
November 2018
3 Reads

Dispensing Patterns of Blood Pressure Lowering Agents in Older Australians From 2006 to 2016.

J Cardiovasc Pharmacol Ther 2018 11 21:1074248418812184. Epub 2018 Nov 21.

1 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Background: Increasing numbers of blood pressure lowering (BPL) agents are being prescribed for both primary and secondary prevention of cardiovascular disease, especially in the older population. The aim of this study is to describe the temporal trends and patterns of BPL dispensing among older Australians (aged ≥65 years).

Methods: We utilized prescription claims data from the Australian Pharmaceutical Benefits Scheme (PBS) for a 10% random sample of people aged ≥65 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418812184DOI Listing
November 2018
24 Reads

Adverse Metabolic Effects of Diltiazem Treatment During Diabetic Cardiomyopathy.

J Cardiovasc Pharmacol Ther 2018 Nov 20:1074248418808392. Epub 2018 Nov 20.

1 College of Pharmacy, The Ohio State University, OH, USA.

Diabetes is a global epidemic disease, which leads to multiorgan dysfunction, including heart disease. Diabetes results from the limited absorption of glucose into insulin-sensitive tissues. The heart is one of the main organs to utilize glucose as an energy substrate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418808392DOI Listing
November 2018
9 Reads

A Thank You From the Editor-in-Chief.

Authors:
Robert A Kloner

J Cardiovasc Pharmacol Ther 2019 Jan 14;24(1):90-91. Epub 2018 Nov 14.

University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418807813DOI Listing
January 2019
1 Read

Effect of Platelet GPIIb/IIIa Receptor Blockade With MK383 on Infarct Size and Myocardial Blood Flow in a Canine Reocclusion Model.

Authors:
John G Kingma

J Cardiovasc Pharmacol Ther 2018 Nov 14:1074248418808389. Epub 2018 Nov 14.

1 Department of Medicine, Faculty of Medicine, Laval University, Pavillon Ferdinand Vandry, Quebec, Canada.

Platelet activation and aggregation during ischemia influence reperfusion-related myocyte necrosis, myocardial perfusion at the microvascular level, and thereby eventual recovery of cardiac performance. Inhibition of platelet activity therefore represents a worthwhile target to reduce cellular injury. The current study examined the effects of MK383 (tirofiban), a potent inhibitor of platelet aggregation, on infarct size and myocardial perfusion in canine subjects to either reocclusion (ie, 120-minute + 60-minute ischemia with intervening reperfusion) or prolonged occlusion (ie, 3 hours) followed by reperfusion (180 minutes). Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418808389
Publisher Site
http://dx.doi.org/10.1177/1074248418808389DOI Listing
November 2018
2 Reads

De-Escalation of Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials.

J Cardiovasc Pharmacol Ther 2018 Nov 12:1074248418809098. Epub 2018 Nov 12.

2 Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.

Aims:: Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) are recommended to be placed on potent P2Y12 blockade. However, the long-term bleeding risk is high. Therefore, despite no definitive evidence, switching to clopidogrel beyond the acute phase is common. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418809098DOI Listing
November 2018
3 Reads

Factors Associated With the Concomitant Use of Cardiovascular Drugs and Dietary Herbal Products: A Cross-Sectional Study.

J Cardiovasc Pharmacol Ther 2018 Sep 27:1074248418794938. Epub 2018 Sep 27.

2 Faculty of Medicine, Department of Cardiology, Kahramanmaras Sutcu Imam University, Kahramanmaraş, Turkey.

Introduction: Dietary herbal products taken together with prescription medicines may have harmful effects. In this study, we evaluated the use of dietary herbal supplements and identified factors that predict the concomitant use of these supplements in patients taking drugs prescribed for chronic cardiovascular diseases.

Methods: We performed a cross-sectional study with 343 patients with cardiovascular diseases. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418794938
Publisher Site
http://dx.doi.org/10.1177/1074248418794938DOI Listing
September 2018
3 Reads

Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model.

J Cardiovasc Pharmacol Ther 2018 Sep 13:1074248418798631. Epub 2018 Sep 13.

3 Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University, Seoul, South Korea.

Objective: Abdominal aortic aneurysm (AAA) is a common condition that may be life-threatening when it is unrecognized. The aim of this study is to evaluate and compare the efficacy of ramipril and carvedilol on limiting AAA expansion in mouse model.

Methods And Results: A total of 36 experimental AAA mouse model was induced with the continuous infusion of angiotensin II (Ang II) in 20-week-old male apolipoprotein E-deficient mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418798631DOI Listing
September 2018
1 Read

Effects of Heart Rate Reduction With Either Pyridostigmine or Ivabradine in Patients With Heart Failure: A Randomized, Double-Blind Study.

J Cardiovasc Pharmacol Ther 2018 Sep 9:1074248418799364. Epub 2018 Sep 9.

1 Postgraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

Background: Heart rate (HR) reduction with ivabradine has been proved to reduce hospitalization and death from heart failure (HF). We sought to investigate whether pyridostigmine would effectively reduce HR in patients with chronic HF as compared with ivabradine.

Methods: Twenty-one patients with HF who were in sinus rhythm with a resting HR over 70 bpm, despite optimal medical treatment, were included in a randomized, double-blind study comparing pyridostigmine versus ivabradine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418799364DOI Listing
September 2018
4 Reads

Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.

J Cardiovasc Pharmacol Ther 2018 Sep 2:1074248418797357. Epub 2018 Sep 2.

4 Clinical Pharmacy Services, Department of Pharmacy, NYU Langone Health, New York, NY, USA.

Inotropes are an integral component of the early stabilization of the patient presenting with cardiogenic shock. Despite years of clinical experience with the 2 most commonly used inotropes, dobutamine and milrinone, there remains limited data comparing outcomes between the two. We conducted a retrospective review to compare the effectiveness and safety of milrinone or dobutamine for the initial management of cardiogenic shock. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418797357DOI Listing
September 2018
3 Reads

Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge.

J Cardiovasc Pharmacol Ther 2018 Aug 21:1074248418795897. Epub 2018 Aug 21.

1 Department of Internal Medicine, Gachon University College of Medicine, Incheon, Republic of Korea.

Aim: Renin-angiotensin-aldosterone system inhibitors (RASIs) are widely used in high-risk cardiovascular (CV) diseases, including acute myocardial infarction (AMI). However, it is not yet clear which class of RASIs provides specific benefits to patients with AMI. The present study aimed to evaluate whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) had any different effects on long-term CV and all-cause mortality in patients with AMI who received either agent from admission and were discharged alive from the hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418795897DOI Listing
August 2018
16 Reads

The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease.

J Cardiovasc Pharmacol Ther 2018 Aug 20:1074248418795889. Epub 2018 Aug 20.

2 Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada.

Despite contemporary management, patients with coronary artery disease (CAD) remain at high risk for thrombotic events. Several randomized controlled trials have evaluated the use of direct oral anticoagulants (DOACs) in patients with CAD, including in the setting of acute coronary syndrome (ACS) and stable CAD, and in patients with concomitant atrial fibrillation. Trials of apixaban and dabigatran in patients with ACS demonstrate no benefit with an increased risk of bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418795889DOI Listing
August 2018
22 Reads
3.072 Impact Factor

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.

J Cardiovasc Pharmacol Ther 2018 Nov 14;23(6):524-531. Epub 2018 Aug 14.

4 Renal Associates, P.A., San Antonio, TX, USA.

Introduction: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin-angiotensin-aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum potassium of hyperkalemic patients similarly when given with or without food; unlike prior studies, patients were not required to be taking RAASi. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418788334
Publisher Site
http://dx.doi.org/10.1177/1074248418788334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193203PMC
November 2018
15 Reads

Approaches to Direct Oral Anticoagulant Selection in Practice.

J Cardiovasc Pharmacol Ther 2018 Aug 9:1074248418793137. Epub 2018 Aug 9.

1 Clinical Pharmacy and Practice Section, College of Pharmacy, Qatar University, Doha, Qatar.

Direct oral anticoagulants (DOACs) carry many advantages over warfarin and are now considered first line or an alternative for mnay thromboembolic disorders. With the emergence of 5 DOAC agents to the market as well as the accumulating evidence gathered from head-to-head comparisons between the agents, we attempt to provide direction for clinicians when selecting the most appropriate DOAC agent. Important aspects such as efficacy, safety, cost effectiveness, approved indications, and other drug-related factors will be addressed to highlight the major similarities and diversities among the DOACs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418793137DOI Listing
August 2018
3 Reads

Utility of the JT Peak Interval and the JT Area in Determining the Proarrhythmic Potential of QT-Shortening Agents.

J Cardiovasc Pharmacol Ther 2018 Aug 9:1074248418791999. Epub 2018 Aug 9.

1 Department of Pharmacology, Hebei Medical University, Shijiazhuang, Hebei, China.

Drug-induced long QT increases the risk of ventricular tachyarrhythmia known as torsades de pointes (TdP). Many biomarkers have been used to predict TdP. At present, however, there are few biomarkers for arrhythmias induced by QT-shortening drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418791999DOI Listing
August 2018
4 Reads

Sodium Nitrite-Mediated Cardioprotection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Cost-Effectiveness Analysis.

J Cardiovasc Pharmacol Ther 2019 Mar 6;24(2):113-119. Epub 2018 Aug 6.

1 Barts NIHR Biomedical Research Centre, Barts and The London Medical School, Queen Mary University, London, United Kingdom.

Objectives:: In the follow-up of patients in a trial of intracoronary sodium nitrite given during primary percutaneous coronary intervention (PCI) after acute myocardial infarction (AMI), we found a reduction in the incidence of major adverse cardiac events (MACEs). Specifically, MACE rates were 5.2% versus 25. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784940DOI Listing
March 2019
11 Reads

Cardiosphere-Derived Cells Attenuate Inflammation, Preserve Systolic Function, and Prevent Adverse Remodeling in Rat Hearts With Experimental Autoimmune Myocarditis.

J Cardiovasc Pharmacol Ther 2019 Jan 30;24(1):70-77. Epub 2018 Jul 30.

1 Third Department of Cardiology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

Background:: Cardiosphere-derived cells (CDCs) have yielded promising efficacy signals in early-phase clinical trials of ischemic and nonischemic cardiomyopathy. The potential efficacy of CDCs in acute myocarditis, an inflammatory cardiomyopathy without effective therapy, remains unexplored. Given that CDCs produce regenerative, cardioprotective, anti-inflammatory, and anti-fibrotic effects (all of which could be beneficial in acute myocarditis), we investigated the efficacy of intracoronary delivery of CDCs in a rat model of experimental autoimmune myocarditis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784287DOI Listing
January 2019
3 Reads

Exercise and Cardioprotection: A Natural Defense Against Lethal Myocardial Ischemia-Reperfusion Injury and Potential Guide to Cardiovascular Prophylaxis.

J Cardiovasc Pharmacol Ther 2019 Jan 24;24(1):18-30. Epub 2018 Jul 24.

1 Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA.

Similar to ischemic preconditioning, high-intensity exercise has been shown to decrease infarct size following myocardial infarction. In this article, we review the literature on beneficial effects of exercise, exercise requirements for cardioprotection, common methods utilized in laboratories to study this phenomenon, and discuss possible mechanisms for exercise-mediated cardioprotection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418788575DOI Listing
January 2019
1 Read

Augmentation of Ouabain-Induced Increase in Heart Muscle Contractility by Akt Inhibitor MK-2206.

J Cardiovasc Pharmacol Ther 2019 Jan 22;24(1):78-89. Epub 2018 Jul 22.

1 Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel.

Cardiac steroids (CSs), such as ouabain and digoxin, increase the force of contraction of heart muscle and are used for the treatment of congestive heart failure (CHF). However, their small therapeutic window limits their use. It is well established that Na, K-ATPase inhibition mediates CS-induced increase in heart contractility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418788301DOI Listing
January 2019
1 Read

Does Ticagrelor Improve Endothelial Function?

J Cardiovasc Pharmacol Ther 2019 Jan 10;24(1):11-17. Epub 2018 Jul 10.

2 Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Ticagrelor is a P2Y receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial function. In light of the common presence and prognostic value of endothelial dysfunction in patients with coronary artery disease, several clinical studies have investigated the postulated effect of ticagrelor on endothelial function, yielding conflicting results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418786936DOI Listing
January 2019
2 Reads

Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia.

J Cardiovasc Pharmacol Ther 2019 Jan 1;24(1):46-53. Epub 2018 Jul 1.

2 University of Tasmania, College of Health and Medicine, Tasmania, Hobart, Australia.

Background:: Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective.

Objective:: To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wales, Australia.

Methods:: This retrospective observational study reviewed patients admitted to St John of God Hawkesbury Hospital with AF between June 2016 and June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418786264DOI Listing
January 2019
2 Reads

The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.

J Cardiovasc Pharmacol Ther 2019 Jan 25;24(1):54-61. Epub 2018 Jun 25.

2 Division of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA.

Background:: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is expressed in multiple tissues, including the small intestine. The effect of PCSK9 inhibition on cholesterol absorption is not known.

Objectives:: Measure serum cholesterol absorption markers before and after initiation of PCSK9 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418780733DOI Listing
January 2019
21 Reads

A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?

J Cardiovasc Pharmacol Ther 2019 Jan 25;24(1):3-10. Epub 2018 Jun 25.

1 Heart and Vascular Institute, Penn State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA.

Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784288DOI Listing
January 2019
2 Reads

Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.

J Cardiovasc Pharmacol Ther 2019 Jan 24;24(1):62-69. Epub 2018 Jun 24.

3 Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background:: Coronary artery disease is the most prevalent manifestation among cardiovascular diseases. Despite modern treatment, risk of ischemic complications in patients with acute coronary syndrome (ACS) remains important. The late Na current blocker ranolazine has shown to reduce the risk of recurrent ischemia and worsening of angina in patients with non-ST-segment elevation ACS by possibly improving myocardial perfusion, but up to now no trial has addressed whether this enhanced perfusion also leads to a decrease in ischemic myocardium of patients with ACS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784290DOI Listing
January 2019
10 Reads

Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure: A Randomized Double-Blind Controlled Pilot Study.

J Cardiovasc Pharmacol Ther 2018 Nov 21;23(6):543-550. Epub 2018 Jun 21.

3 CIBERCV Instituto de Salud Carlos III, Madrid, Spain.

Background: Testosterone deficiency is associated with heart failure (HF) progression and poor prognosis. Testosterone therapy has been shown to improve exercise capacity in patients with chronic HF, but no trial has evaluated the impact of replacement in patients with demonstrated testosterone deficiency.

Methods: Prospective, randomized, double-blind, placebo-controlled, and parallel-group trial comparing testosterone replacement with placebo in males with chronic HF with reduced ejection fraction (HFrEF) and testosterone deficiency (NCT01813201). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784020DOI Listing
November 2018
26 Reads

Quality of Life and Its Association With Treatment Satisfaction, Adherence to Medication, and Trust in Physician Among Patients With Hypertension: A Cross-Sectional Designed Study.

J Cardiovasc Pharmacol Ther 2018 Nov 19;23(6):532-542. Epub 2018 Jun 19.

1 Pharmacology, Clinical Pharmacy and Quality Control Laboratory, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut, Lebanon.

Objective: Patients with hypertension tend to have a lower health-related quality of life (HRQOL) compared to normotensive patients. This study's main objectives are to assess (1) HRQOL and factors that might impact it and (2) association between HRQOL and adherence to treatment, trust in physician, and treatment satisfaction among patients with hypertension.

Methods: A cross-sectional study enrolled 196 patients from medical-care offices in Beirut, North and South Lebanon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418784292DOI Listing
November 2018
6 Reads

Anticoagulation Therapy in Specific Cardiomyopathies: Isolated Left Ventricular Noncompaction and Peripartum Cardiomyopathy.

J Cardiovasc Pharmacol Ther 2019 Jan 18;24(1):31-36. Epub 2018 Jun 18.

3 Gill Heart Institute, University of Kentucky HealthCare, Lexington, KY, USA.

In 2 distinct entities, left ventricular noncompaction (LVNC) and peripartum cardiomyopathy (PPCM), routine anticoagulation therapy is often used in current practices. However, our systematic review showed that LVNC itself was not associated with the increase in thromboembolism event rates and therapeutic anticoagulation therapy should not be considered only for LVNC, unless there is risk factor for thromboembolism. Current literature justifies prophylactic therapeutic anticoagulation in LVNC with low left ventricular ejection fraction (EF < 40%) and/or atrial fibrillation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418783745DOI Listing
January 2019
24 Reads

Corrigendum.

Authors:

J Cardiovasc Pharmacol Ther 2018 Jul;23(4):372

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418777807DOI Listing
July 2018
2 Reads

Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.

J Cardiovasc Pharmacol Ther 2018 Nov 27;23(6):502-508. Epub 2018 May 27.

3 Center for Health Equity and Quality Research, University of Florida, FL, USA.

Background: Risk stratification for stroke in patients with atrial fibrillation is a vital step in identifying whether antithrombotic therapy is indicated for stroke prevention in this common arrhythmia.

Purpose: The aim of this study was to determine adherence to guideline-directed antithrombotic therapy based on Congestive Heart Failure (1 point), Hypertension (1 point), Age (≥75 years old is 2 points and 65-74 is 1 point), Diabetes (1 point), prior Stroke (2 points), Vascular Disease (1 point), and Sex Category (1 point if female; CHADS-VASc) score in patients with atrial fibrillation (AF) on hospital discharge.

Methods: A total of 293 patients discharged from this academic medical center with a history of atrial fibrillation from June 2014 to June 2016 were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418778804DOI Listing
November 2018
2 Reads

The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study.

J Cardiovasc Pharmacol Ther 2019 Jan 24;24(1):37-45. Epub 2018 May 24.

4 Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center +, Maastricht, the Netherlands.

Purpose:: β-Blockers (BBs) have been associated with a reduced cardiorespiratory fitness (CRF). This is possibly caused by inhibition of β2-receptors in the airways. However, there are limited data available on β-receptor selectivity and CRF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418778551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297897PMC
January 2019
6 Reads

Effect of β-blocker Therapy on Hospital Readmission and Mortality in Heart Failure Patients With Concurrent Cocaine Use.

J Cardiovasc Pharmacol Ther 2018 Nov 24;23(6):518-523. Epub 2018 May 24.

2 Division of Cardiology, Morehouse School of Medicine, Atlanta, GA, USA.

Background: β-Blockers are first-line agents for reduction in symptoms, hospitalization, and mortality in patients with heart failure having reduced ejection fraction (HFrEF). However, the safety and efficacy of continuous β-blocker therapy (BBT) in patients who actively use cocaine remain controversial, and available literature is limited. We aimed to evaluate the effect of BBT on hospital readmission and mortality in patients having HFrEF with concurrent cocaine use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418778550DOI Listing
November 2018
7 Reads

Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.

J Cardiovasc Pharmacol Ther 2018 Nov 23;23(6):494-501. Epub 2018 May 23.

1 Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAPJGol), Barcelona, Spain.

Background: Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and a better safety profile compared to warfarin.

Objectives: (1) To describe the characteristics of patients with nonvalvular atrial fibrillation beginning treatment with apixaban, (2) to analyze concomitant prescriptions of medications that could potentially interact with apixaban, (3) to evaluate the level of appropriate usage according to the recommended dosage, and (4) to estimate the level of apixaban persistence among naive and non-naive patients. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418778544
Publisher Site
http://dx.doi.org/10.1177/1074248418778544DOI Listing
November 2018
7 Reads

The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.

J Cardiovasc Pharmacol Ther 2018 Nov 21;23(6):483-493. Epub 2018 May 21.

2 Department of Medicine, The Chicago Medical School, Rosalind Franklin University, North Chicago, IL, USA.

Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an important role in atherothrombosis independent of the cholesterol level. Acute-phase reactants, such as C-reactive protein, increase in patients with coronary artery disease and are known to predict adverse outcomes in such patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418778548DOI Listing
November 2018
1 Read

Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles.

J Cardiovasc Pharmacol Ther 2018 Nov 20;23(6):561-569. Epub 2018 May 20.

1 Heart Institute (InCor) of the Medical School Hospital University of São Paulo, São Paulo, Brazil.

In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LDE-PTX treatment with methotrexate (MTX) associated with LDE (LDE-MTX) could accelerate the atherosclerosis regression attained with single LDE-PTX treatment, after withdrawing the cholesterol feeding. Thirty-eight rabbits were fed 1% cholesterol chow for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418778836DOI Listing
November 2018
44 Reads

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

J Cardiovasc Pharmacol Ther 2018 Sep 16;23(5):423-432. Epub 2018 May 16.

5 Clinical Pharmacology, Amgen Inc, Thousand Oaks, CA, USA.

Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of cardiovascular events.

Objectives: To compare LDL-C reduction using evolocumab 140 mg once every 2 weeks (Q2W) or 420 mg monthly (QM) versus lower doses (70 mg Q2W or 280 mg QM) or placebo.

Methods: Patients received evolocumab 70 or 140 mg Q2W, 280 or 420 mg QM, or placebo Q2W or QM in two 12-week phase 2 studies: one with and one without statins. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1074248418774043
Publisher Site
http://dx.doi.org/10.1177/1074248418774043DOI Listing
September 2018
9 Reads

Simvastatin Suppresses Interleukin Iβ Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals.

J Cardiovasc Pharmacol Ther 2018 Nov 15;23(6):509-517. Epub 2018 May 15.

1 Department of Pharmacology and Therapeutics, School of Medicine, Trinity College Dublin, Ireland.

Statins are mainstream therapy in the treatment and prevention of cardiovascular disease through inhibitory effects on cholesterol synthesis. However, statins' beneficial effects in cardiovascular disease may also be attributable to their role as anti-inflammatory mediators. Here, we investigated the effects of simvastatin treatment on expression levels of interleukin (IL) 1β in both patient with hyperlipidemia and healthy human peripheral blood mononuclear cells (PBMCs) using cholesterol crystals (CC), a cardiovascular pathogenic stimulus for activation of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248418776261DOI Listing
November 2018
5 Reads